ID   DOCK8_HUMAN             Reviewed;        2099 AA.
AC   Q8NF50; A2A350; A2BDF2; A4FU78; B7ZLP0; E9PH09; Q3MV16; Q5JPJ1; Q8TEP1;
AC   Q8WUY2; Q9BYJ5; Q9H1Q2; Q9H1Q3; Q9H308; Q9H7P2;
DT   03-JUL-2003, integrated into UniProtKB/Swiss-Prot.
DT   21-AUG-2007, sequence version 3.
DT   28-JUN-2023, entry version 180.
DE   RecName: Full=Dedicator of cytokinesis protein 8;
GN   Name=DOCK8;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT THR-97.
RC   TISSUE=Lung;
RA   Takahashi K., Kohno T., Yokota J.;
RT   "DOCK8, a candidate tumor suppressor gene.";
RL   Submitted (SEP-2004) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164053; DOI=10.1038/nature02465;
RA   Humphray S.J., Oliver K., Hunt A.R., Plumb R.W., Loveland J.E., Howe K.L.,
RA   Andrews T.D., Searle S., Hunt S.E., Scott C.E., Jones M.C., Ainscough R.,
RA   Almeida J.P., Ambrose K.D., Ashwell R.I.S., Babbage A.K., Babbage S.,
RA   Bagguley C.L., Bailey J., Banerjee R., Barker D.J., Barlow K.F., Bates K.,
RA   Beasley H., Beasley O., Bird C.P., Bray-Allen S., Brown A.J., Brown J.Y.,
RA   Burford D., Burrill W., Burton J., Carder C., Carter N.P., Chapman J.C.,
RA   Chen Y., Clarke G., Clark S.Y., Clee C.M., Clegg S., Collier R.E.,
RA   Corby N., Crosier M., Cummings A.T., Davies J., Dhami P., Dunn M.,
RA   Dutta I., Dyer L.W., Earthrowl M.E., Faulkner L., Fleming C.J.,
RA   Frankish A., Frankland J.A., French L., Fricker D.G., Garner P.,
RA   Garnett J., Ghori J., Gilbert J.G.R., Glison C., Grafham D.V., Gribble S.,
RA   Griffiths C., Griffiths-Jones S., Grocock R., Guy J., Hall R.E.,
RA   Hammond S., Harley J.L., Harrison E.S.I., Hart E.A., Heath P.D.,
RA   Henderson C.D., Hopkins B.L., Howard P.J., Howden P.J., Huckle E.,
RA   Johnson C., Johnson D., Joy A.A., Kay M., Keenan S., Kershaw J.K.,
RA   Kimberley A.M., King A., Knights A., Laird G.K., Langford C., Lawlor S.,
RA   Leongamornlert D.A., Leversha M., Lloyd C., Lloyd D.M., Lovell J.,
RA   Martin S., Mashreghi-Mohammadi M., Matthews L., McLaren S., McLay K.E.,
RA   McMurray A., Milne S., Nickerson T., Nisbett J., Nordsiek G., Pearce A.V.,
RA   Peck A.I., Porter K.M., Pandian R., Pelan S., Phillimore B., Povey S.,
RA   Ramsey Y., Rand V., Scharfe M., Sehra H.K., Shownkeen R., Sims S.K.,
RA   Skuce C.D., Smith M., Steward C.A., Swarbreck D., Sycamore N., Tester J.,
RA   Thorpe A., Tracey A., Tromans A., Thomas D.W., Wall M., Wallis J.M.,
RA   West A.P., Whitehead S.L., Willey D.L., Williams S.A., Wilming L.,
RA   Wray P.W., Young L., Ashurst J.L., Coulson A., Blocker H., Durbin R.M.,
RA   Sulston J.E., Hubbard T., Jackson M.J., Bentley D.R., Beck S., Rogers J.,
RA   Dunham I.;
RT   "DNA sequence and analysis of human chromosome 9.";
RL   Nature 429:369-374(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 3 AND 4), NUCLEOTIDE
RP   SEQUENCE [LARGE SCALE MRNA] OF 53-2099 (ISOFORM 2), AND VARIANT SER-413.
RC   TISSUE=Brain, Muscle, and Testis;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 53-2099 (ISOFORM 1).
RC   TISSUE=Lymph node;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 301-2099 (ISOFORM 1).
RC   TISSUE=Spleen;
RX   PubMed=12693554; DOI=10.1093/dnares/10.1.49;
RA   Jikuya H., Takano J., Kikuno R., Hirosawa M., Nagase T., Nomura N.,
RA   Ohara O.;
RT   "Characterization of long cDNA clones from human adult spleen. II. The
RT   complete sequences of 81 cDNA clones.";
RL   DNA Res. 10:49-57(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 591-2099 (ISOFORM 1).
RC   TISSUE=Spleen;
RA   Jikuya H., Takano J., Nomura N., Kikuno R., Nagase T., Ohara O.;
RT   "The nucleotide sequence of a long cDNA clone isolated from human spleen.";
RL   Submitted (FEB-2002) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 920-2099 (ISOFORM 1).
RC   TISSUE=Spleen;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1775-2099, AND VARIANT PRO-1970.
RX   PubMed=10729223; DOI=10.1006/geno.2000.6121;
RA   Ottolenghi C., Veitia R., Quintana-Murci L., Torchard D., Scapoli L.,
RA   Souleyreau-Therville N., Beckmann J., Fellous M., McElreavey K.;
RT   "The region on 9p associated with 46,XY sex reversal contains several
RT   transcripts expressed in the urogenital system and a novel doublesex-
RT   related domain.";
RL   Genomics 64:170-178(2000).
RN   [9]
RP   NOMENCLATURE.
RX   PubMed=12432077; DOI=10.1242/jcs.00219;
RA   Cote J.-F., Vuori K.;
RT   "Identification of an evolutionarily conserved superfamily of DOCK180-
RT   related proteins with guanine nucleotide exchange activity.";
RL   J. Cell Sci. 115:4901-4913(2002).
RN   [10]
RP   CHROMOSOMAL TRANSLOCATION, AND INVOLVEMENT IN MRD2.
RX   PubMed=18060736; DOI=10.1016/j.ygeno.2007.10.011;
RA   Griggs B.L., Ladd S., Saul R.A., DuPont B.R., Srivastava A.K.;
RT   "Dedicator of cytokinesis 8 is disrupted in two patients with mental
RT   retardation and developmental disabilities.";
RL   Genomics 91:195-202(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-451, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-451, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [13]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [14]
RP   FUNCTION, INTERACTION WITH CDC42, AND DOMAIN.
RX   PubMed=22461490; DOI=10.1182/blood-2012-01-407098;
RA   Harada Y., Tanaka Y., Terasawa M., Pieczyk M., Habiro K., Katakai T.,
RA   Hanawa-Suetsugu K., Kukimoto-Niino M., Nishizaki T., Shirouzu M., Duan X.,
RA   Uruno T., Nishikimi A., Sanematsu F., Yokoyama S., Stein J.V., Kinashi T.,
RA   Fukui Y.;
RT   "DOCK8 is a Cdc42 activator critical for interstitial dendritic cell
RT   migration during immune responses.";
RL   Blood 119:4451-4461(2012).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-20; SER-139; SER-451;
RP   SER-936; SER-1145 AND SER-2087, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [16]
RP   FUNCTION, AND INTERACTION WITH CCDC88B.
RX   PubMed=25762780; DOI=10.4049/jimmunol.1402897;
RA   Ham H., Huynh W., Schoon R.A., Vale R.D., Billadeau D.D.;
RT   "HkRP3 is a microtubule-binding protein regulating lytic granule clustering
RT   and NK cell killing.";
RL   J. Immunol. 194:3984-3996(2015).
RN   [17]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [18]
RP   FUNCTION, INTERACTION WITH LRCH1 AND CDC42, SUBCELLULAR LOCATION, TISSUE
RP   SPECIFICITY, DOMAIN, PHOSPHORYLATION, AND MUTAGENESIS OF SER-2077; SER-2082
RP   AND SER-2087.
RX   PubMed=28028151; DOI=10.1084/jem.20160068;
RA   Xu X., Han L., Zhao G., Xue S., Gao Y., Xiao J., Zhang S., Chen P.,
RA   Wu Z.Y., Ding J., Hu R., Wei B., Wang H.;
RT   "LRCH1 interferes with DOCK8-Cdc42-induced T cell migration and ameliorates
RT   experimental autoimmune encephalomyelitis.";
RL   J. Exp. Med. 214:209-226(2017).
RN   [19]
RP   VARIANT HIES2 ARG-473.
RX   PubMed=19776401; DOI=10.1056/nejmoa0905506;
RA   Zhang Q., Davis J.C., Lamborn I.T., Freeman A.F., Jing H., Favreau A.J.,
RA   Matthews H.F., Davis J., Turner M.L., Uzel G., Holland S.M., Su H.C.;
RT   "Combined immunodeficiency associated with DOCK8 mutations.";
RL   N. Engl. J. Med. 361:2046-2055(2009).
RN   [20]
RP   VARIANT VAL-652.
RX   PubMed=24169519; DOI=10.1038/ejhg.2013.243;
RA   Piton A., Poquet H., Redin C., Masurel A., Lauer J., Muller J.,
RA   Thevenon J., Herenger Y., Chancenotte S., Bonnet M., Pinoit J.M., Huet F.,
RA   Thauvin-Robinet C., Jaeger A.S., Le Gras S., Jost B., Gerard B., Peoc'h K.,
RA   Launay J.M., Faivre L., Mandel J.L.;
RT   "20 ans apres: a second mutation in MAOA identified by targeted high-
RT   throughput sequencing in a family with altered behavior and cognition.";
RL   Eur. J. Hum. Genet. 22:776-783(2014).
CC   -!- FUNCTION: Guanine nucleotide exchange factor (GEF) which specifically
CC       activates small GTPase CDC42 by exchanging bound GDP for free GTP
CC       (PubMed:28028151, PubMed:22461490). During immune responses, required
CC       for interstitial dendritic cell (DC) migration by locally activating
CC       CDC42 at the leading edge membrane of DC (By similarity). Required for
CC       CD4(+) T-cell migration in response to chemokine stimulation by
CC       promoting CDC42 activation at T cell leading edge membrane
CC       (PubMed:28028151). Is involved in NK cell cytotoxicity by controlling
CC       polarization of microtubule-organizing center (MTOC), and possibly
CC       regulating CCDC88B-mediated lytic granule transport to MTOC during cell
CC       killing (PubMed:25762780). {ECO:0000250|UniProtKB:Q8C147,
CC       ECO:0000269|PubMed:22461490, ECO:0000269|PubMed:25762780,
CC       ECO:0000269|PubMed:28028151}.
CC   -!- SUBUNIT: Interacts (via DOCKER domain) with GTPase CDC42; the
CC       interaction activates CDC42 by exchanging GDP for GTP (PubMed:22461490,
CC       PubMed:28028151). The unphosphorylated form interacts (via DOCKER
CC       domain) with LRCH1 (via LRR repeats); the interaction prevents the
CC       association between DOCK8 and CDC42 (PubMed:28028151). Interacts with
CC       CCDC88B (PubMed:25762780). {ECO:0000269|PubMed:22461490,
CC       ECO:0000269|PubMed:25762780, ECO:0000269|PubMed:28028151}.
CC   -!- INTERACTION:
CC       Q8NF50; Q9Y2V2: CARHSP1; NbExp=3; IntAct=EBI-2548605, EBI-718719;
CC       Q8NF50; Q6A162: KRT40; NbExp=3; IntAct=EBI-2548605, EBI-10171697;
CC       Q8NF50; Q9Y2L9: LRCH1; NbExp=3; IntAct=EBI-2548605, EBI-2797324;
CC       Q8NF50; Q5VUJ6: LRCH2; NbExp=4; IntAct=EBI-2548605, EBI-2659666;
CC       Q8NF50; P50222: MEOX2; NbExp=3; IntAct=EBI-2548605, EBI-748397;
CC       Q8NF50; Q99836: MYD88; NbExp=3; IntAct=EBI-2548605, EBI-447677;
CC       Q8NF50; Q9BSJ6: PIMREG; NbExp=3; IntAct=EBI-2548605, EBI-2568609;
CC       Q8NF50-2; Q13895: BYSL; NbExp=5; IntAct=EBI-10174653, EBI-358049;
CC       Q8NF50-2; Q9Y2V2: CARHSP1; NbExp=3; IntAct=EBI-10174653, EBI-718719;
CC       Q8NF50-2; O43633: CHMP2A; NbExp=3; IntAct=EBI-10174653, EBI-2692789;
CC       Q8NF50-2; Q9NQT4: EXOSC5; NbExp=3; IntAct=EBI-10174653, EBI-371876;
CC       Q8NF50-2; Q86V42: FAM124A; NbExp=3; IntAct=EBI-10174653, EBI-744506;
CC       Q8NF50-2; Q3B820: FAM161A; NbExp=3; IntAct=EBI-10174653, EBI-719941;
CC       Q8NF50-2; Q9NW38: FANCL; NbExp=3; IntAct=EBI-10174653, EBI-2339898;
CC       Q8NF50-2; Q9NXK8: FBXL12; NbExp=3; IntAct=EBI-10174653, EBI-719790;
CC       Q8NF50-2; P02008: HBZ; NbExp=3; IntAct=EBI-10174653, EBI-719843;
CC       Q8NF50-2; Q9Y2L9: LRCH1; NbExp=5; IntAct=EBI-10174653, EBI-2797324;
CC       Q8NF50-2; Q96II8: LRCH3; NbExp=3; IntAct=EBI-10174653, EBI-8795942;
CC       Q8NF50-2; Q96HR3: MED30; NbExp=3; IntAct=EBI-10174653, EBI-394659;
CC       Q8NF50-2; B2R894: MRPL38; NbExp=3; IntAct=EBI-10174653, EBI-7825143;
CC       Q8NF50-2; Q14D33: RTP5; NbExp=3; IntAct=EBI-10174653, EBI-10217913;
CC       Q8NF50-2; G3V1X1: ZFC3H1; NbExp=3; IntAct=EBI-10174653, EBI-6448783;
CC       Q8NF50-2; Q9P0T4: ZNF581; NbExp=3; IntAct=EBI-10174653, EBI-745520;
CC       Q8NF50-2; A8K900; NbExp=3; IntAct=EBI-10174653, EBI-10174650;
CC       Q8NF50-3; O75427: LRCH4; NbExp=2; IntAct=EBI-25409271, EBI-718707;
CC       Q8NF50-4; Q9Y2V7: COG6; NbExp=3; IntAct=EBI-12021848, EBI-3866319;
CC       Q8NF50-4; O75031: HSF2BP; NbExp=3; IntAct=EBI-12021848, EBI-7116203;
CC       Q8NF50-4; Q6FHY5: MEOX2; NbExp=3; IntAct=EBI-12021848, EBI-16439278;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:28028151}. Cell
CC       membrane {ECO:0000269|PubMed:28028151}; Peripheral membrane protein
CC       {ECO:0000305|PubMed:28028151}; Cytoplasmic side {ECO:0000305}. Cell
CC       projection, lamellipodium membrane {ECO:0000269|PubMed:28028151};
CC       Peripheral membrane protein {ECO:0000305|PubMed:28028151}; Cytoplasmic
CC       side {ECO:0000305}. Note=Enriched and co-localizes with GTPase CDC42 at
CC       the immunological synapse formed during T cell/antigen presenting cell
CC       cognate interaction. Translocates from the cytoplasm to the plasma
CC       membrane in response to chemokine CXCL12/SDF-1-alpha stimulation.
CC       {ECO:0000269|PubMed:28028151}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q8NF50-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q8NF50-2; Sequence=VSP_027373;
CC       Name=3;
CC         IsoId=Q8NF50-3; Sequence=VSP_039838;
CC       Name=4;
CC         IsoId=Q8NF50-4; Sequence=VSP_039838, VSP_027373;
CC   -!- TISSUE SPECIFICITY: Expressed in peripheral blood mononuclear cells
CC       (PBMCs). {ECO:0000269|PubMed:28028151}.
CC   -!- DOMAIN: The DOCKER domain is necessary and sufficient for the GEF
CC       activity. {ECO:0000269|PubMed:22461490, ECO:0000269|PubMed:28028151}.
CC   -!- PTM: In response to chemokine CXCL12/SDF-1-alpha stimulation,
CC       phosphorylated by PRKCA/PKC-alpha which promotes DOCK8 dissociation
CC       from LRCH1. {ECO:0000269|PubMed:28028151}.
CC   -!- DISEASE: Hyper-IgE recurrent infection syndrome 2, autosomal recessive
CC       (HIES2) [MIM:243700]: A rare disorder characterized by
CC       immunodeficiency, recurrent infections, eczema, increased serum IgE,
CC       eosinophilia and lack of connective tissue and skeletal involvement.
CC       {ECO:0000269|PubMed:19776401}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Intellectual developmental disorder, autosomal dominant 2
CC       (MRD2) [MIM:614113]: A disorder characterized by significantly below
CC       average general intellectual functioning associated with impairments in
CC       adaptive behavior and manifested during the developmental period.
CC       {ECO:0000269|PubMed:18060736}. Note=The gene represented in this entry
CC       is involved in disease pathogenesis. A chromosomal aberration
CC       disrupting DOCK8 has been found in a patient with intellectual
CC       disability and ectodermal dysplasia. A balanced translocation, t(X;9)
CC       (q13.1;p24). A genomic deletion of approximately 230 kb in subtelomeric
CC       9p has been detected in a patient with intellectual disability.
CC   -!- SIMILARITY: Belongs to the DOCK family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00983}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=AAG42221.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=BAB84907.1; Type=Frameshift; Evidence={ECO:0000305};
CC       Sequence=CAI46160.1; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AB191037; BAE45254.1; -; mRNA.
DR   EMBL; AL158832; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL161725; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC019102; AAH19102.2; -; mRNA.
DR   EMBL; BC112894; AAI12895.1; -; mRNA.
DR   EMBL; BC130518; AAI30519.1; -; mRNA.
DR   EMBL; BC143929; AAI43930.1; -; mRNA.
DR   EMBL; AL583913; CAC29497.1; -; mRNA.
DR   EMBL; AL832270; CAI46160.1; ALT_INIT; mRNA.
DR   EMBL; AK090429; BAC03410.1; -; mRNA.
DR   EMBL; AK074081; BAB84907.1; ALT_FRAME; mRNA.
DR   EMBL; AK024436; BAB15726.1; -; mRNA.
DR   EMBL; AF194407; AAG42221.1; ALT_FRAME; mRNA.
DR   CCDS; CCDS55283.1; -. [Q8NF50-3]
DR   CCDS; CCDS55284.1; -. [Q8NF50-4]
DR   CCDS; CCDS6440.2; -. [Q8NF50-1]
DR   RefSeq; NP_001177387.1; NM_001190458.1. [Q8NF50-4]
DR   RefSeq; NP_001180465.1; NM_001193536.1. [Q8NF50-3]
DR   RefSeq; NP_982272.2; NM_203447.3. [Q8NF50-1]
DR   RefSeq; XP_011516347.1; XM_011518045.2. [Q8NF50-4]
DR   RefSeq; XP_011516349.1; XM_011518047.2.
DR   RefSeq; XP_011516350.1; XM_011518048.2.
DR   RefSeq; XP_016870662.1; XM_017015173.1. [Q8NF50-3]
DR   AlphaFoldDB; Q8NF50; -.
DR   SMR; Q8NF50; -.
DR   BioGRID; 123577; 121.
DR   CORUM; Q8NF50; -.
DR   IntAct; Q8NF50; 107.
DR   MINT; Q8NF50; -.
DR   STRING; 9606.ENSP00000394888; -.
DR   GlyCosmos; Q8NF50; 2 sites, 1 glycan.
DR   GlyGen; Q8NF50; 2 sites, 1 O-linked glycan (2 sites).
DR   iPTMnet; Q8NF50; -.
DR   PhosphoSitePlus; Q8NF50; -.
DR   BioMuta; DOCK8; -.
DR   DMDM; 158937439; -.
DR   EPD; Q8NF50; -.
DR   jPOST; Q8NF50; -.
DR   MassIVE; Q8NF50; -.
DR   MaxQB; Q8NF50; -.
DR   PaxDb; Q8NF50; -.
DR   PeptideAtlas; Q8NF50; -.
DR   ProteomicsDB; 20435; -.
DR   ProteomicsDB; 73260; -. [Q8NF50-1]
DR   ProteomicsDB; 73261; -. [Q8NF50-2]
DR   ProteomicsDB; 73262; -. [Q8NF50-3]
DR   Antibodypedia; 758; 350 antibodies from 27 providers.
DR   DNASU; 81704; -.
DR   Ensembl; ENST00000432829.7; ENSP00000394888.3; ENSG00000107099.18. [Q8NF50-1]
DR   Ensembl; ENST00000453981.5; ENSP00000408464.2; ENSG00000107099.18. [Q8NF50-3]
DR   Ensembl; ENST00000469391.5; ENSP00000419438.1; ENSG00000107099.18. [Q8NF50-4]
DR   GeneID; 81704; -.
DR   KEGG; hsa:81704; -.
DR   MANE-Select; ENST00000432829.7; ENSP00000394888.3; NM_203447.4; NP_982272.2.
DR   UCSC; uc003zgf.2; human. [Q8NF50-1]
DR   AGR; HGNC:19191; -.
DR   CTD; 81704; -.
DR   DisGeNET; 81704; -.
DR   GeneCards; DOCK8; -.
DR   HGNC; HGNC:19191; DOCK8.
DR   HPA; ENSG00000107099; Tissue enhanced (choroid plexus, lymphoid tissue).
DR   MalaCards; DOCK8; -.
DR   MIM; 243700; phenotype.
DR   MIM; 611432; gene.
DR   MIM; 614113; phenotype.
DR   neXtProt; NX_Q8NF50; -.
DR   OpenTargets; ENSG00000107099; -.
DR   Orphanet; 178469; Autosomal dominant non-syndromic intellectual disability.
DR   Orphanet; 641368; Autosomal recessive hyper-IgE syndrome.
DR   Orphanet; 217390; Combined immunodeficiency due to DOCK8 deficiency.
DR   PharmGKB; PA134918866; -.
DR   VEuPathDB; HostDB:ENSG00000107099; -.
DR   eggNOG; KOG1997; Eukaryota.
DR   GeneTree; ENSGT00940000155876; -.
DR   HOGENOM; CLU_000624_0_0_1; -.
DR   InParanoid; Q8NF50; -.
DR   OMA; MMERKIP; -.
DR   OrthoDB; 5480873at2759; -.
DR   PhylomeDB; Q8NF50; -.
DR   TreeFam; TF313629; -.
DR   PathwayCommons; Q8NF50; -.
DR   Reactome; R-HSA-9013148; CDC42 GTPase cycle.
DR   Reactome; R-HSA-9013149; RAC1 GTPase cycle.
DR   Reactome; R-HSA-9013409; RHOJ GTPase cycle.
DR   Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production.
DR   SignaLink; Q8NF50; -.
DR   SIGNOR; Q8NF50; -.
DR   BioGRID-ORCS; 81704; 9 hits in 1153 CRISPR screens.
DR   ChiTaRS; DOCK8; human.
DR   GeneWiki; Dock8; -.
DR   GenomeRNAi; 81704; -.
DR   Pharos; Q8NF50; Tbio.
DR   PRO; PR:Q8NF50; -.
DR   Proteomes; UP000005640; Chromosome 9.
DR   RNAct; Q8NF50; protein.
DR   Bgee; ENSG00000107099; Expressed in bone marrow cell and 166 other tissues.
DR   ExpressionAtlas; Q8NF50; baseline and differential.
DR   Genevisible; Q8NF50; HS.
DR   GO; GO:0031252; C:cell leading edge; IBA:GO_Central.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0031258; C:lamellipodium membrane; IEA:UniProtKB-SubCell.
DR   GO; GO:0031256; C:leading edge membrane; IDA:UniProtKB.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; IDA:UniProtKB.
DR   GO; GO:1990869; P:cellular response to chemokine; IMP:UniProtKB.
DR   GO; GO:0036336; P:dendritic cell migration; IEA:Ensembl.
DR   GO; GO:0001771; P:immunological synapse formation; IEA:Ensembl.
DR   GO; GO:0061485; P:memory T cell proliferation; IMP:MGI.
DR   GO; GO:0070233; P:negative regulation of T cell apoptotic process; IEA:Ensembl.
DR   GO; GO:1903905; P:positive regulation of establishment of T cell polarity; IMP:UniProtKB.
DR   GO; GO:0043547; P:positive regulation of GTPase activity; IDA:UniProtKB.
DR   GO; GO:2000406; P:positive regulation of T cell migration; IMP:UniProtKB.
DR   GO; GO:0051056; P:regulation of small GTPase mediated signal transduction; TAS:Reactome.
DR   GO; GO:0007264; P:small GTPase mediated signal transduction; IEA:InterPro.
DR   CDD; cd08696; C2_Dock-C; 1.
DR   CDD; cd11701; DHR2_DOCK8; 1.
DR   Gene3D; 1.20.58.740; -; 1.
DR   Gene3D; 1.25.40.410; -; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR037808; C2_Dock-C.
DR   InterPro; IPR027007; C2_DOCK-type_domain.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR026791; DOCK.
DR   InterPro; IPR021816; DOCK_C/D_N.
DR   InterPro; IPR043161; DOCK_C_lobe_A.
DR   InterPro; IPR043162; DOCK_C_lobe_C.
DR   InterPro; IPR027357; DOCKER_dom.
DR   InterPro; IPR046769; DOCKER_Lobe_A.
DR   InterPro; IPR046770; DOCKER_Lobe_B.
DR   InterPro; IPR046773; DOCKER_Lobe_C.
DR   PANTHER; PTHR23317; DEDICATOR OF CYTOKINESIS DOCK; 1.
DR   PANTHER; PTHR23317:SF74; DEDICATOR OF CYTOKINESIS PROTEIN 8; 1.
DR   Pfam; PF06920; DHR-2_Lobe_A; 1.
DR   Pfam; PF20422; DHR-2_Lobe_B; 1.
DR   Pfam; PF20421; DHR-2_Lobe_C; 1.
DR   Pfam; PF14429; DOCK-C2; 1.
DR   Pfam; PF11878; DOCK_C-D_N; 1.
DR   SUPFAM; SSF48371; ARM repeat; 1.
DR   PROSITE; PS51650; C2_DOCK; 1.
DR   PROSITE; PS51651; DOCKER; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Cell projection;
KW   Chromosomal rearrangement; Cytoplasm; Disease variant;
KW   Guanine-nucleotide releasing factor; Intellectual disability; Membrane;
KW   Phosphoprotein; Reference proteome.
FT   CHAIN           1..2099
FT                   /note="Dedicator of cytokinesis protein 8"
FT                   /id="PRO_0000189997"
FT   DOMAIN          560..729
FT                   /note="C2 DOCK-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00983"
FT   DOMAIN          1632..2066
FT                   /note="DOCKER"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00984"
FT   MOD_RES         20
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         139
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         451
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19369195,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:23186163"
FT   MOD_RES         904
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8C147"
FT   MOD_RES         936
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1145
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1243
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q8C147"
FT   MOD_RES         2087
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         1..68
FT                   /note="Missing (in isoform 3 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_039838"
FT   VAR_SEQ         927..958
FT                   /note="Missing (in isoform 2 and isoform 4)"
FT                   /evidence="ECO:0000303|PubMed:15489334"
FT                   /id="VSP_027373"
FT   VARIANT         97
FT                   /note="P -> T (in dbSNP:rs529208)"
FT                   /evidence="ECO:0000269|Ref.1"
FT                   /id="VAR_033888"
FT   VARIANT         169
FT                   /note="E -> K (in dbSNP:rs11789099)"
FT                   /id="VAR_059972"
FT   VARIANT         237
FT                   /note="E -> K (in dbSNP:rs11789099)"
FT                   /id="VAR_033889"
FT   VARIANT         413
FT                   /note="N -> S (in dbSNP:rs10970979)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_033890"
FT   VARIANT         473
FT                   /note="K -> R (in HIES2; dbSNP:rs112321280)"
FT                   /evidence="ECO:0000269|PubMed:19776401"
FT                   /id="VAR_063753"
FT   VARIANT         597
FT                   /note="A -> V (in dbSNP:rs17673268)"
FT                   /id="VAR_033891"
FT   VARIANT         652
FT                   /note="I -> V (in dbSNP:rs1381340726)"
FT                   /evidence="ECO:0000269|PubMed:24169519"
FT                   /id="VAR_071964"
FT   VARIANT         1008
FT                   /note="R -> W (in dbSNP:rs16937932)"
FT                   /id="VAR_033892"
FT   VARIANT         1970
FT                   /note="A -> P (in dbSNP:rs34908836)"
FT                   /evidence="ECO:0000269|PubMed:10729223"
FT                   /id="VAR_033893"
FT   MUTAGEN         2077
FT                   /note="S->A: Abolishes phosphorylation. No migration in
FT                   response to chemokine CXCL12/SDF-1-alpha stimulation; when
FT                   associated with A-2082 and A-2087."
FT                   /evidence="ECO:0000269|PubMed:28028151"
FT   MUTAGEN         2077
FT                   /note="S->E: Phosphomimetic mutant. Enhances migration in
FT                   response to chemokine CXCL12/SDF-1-alpha stimulation and
FT                   reduces interaction with LRCH1; when associated with E-2082
FT                   and E-2087."
FT                   /evidence="ECO:0000269|PubMed:28028151"
FT   MUTAGEN         2082
FT                   /note="S->A: Abolishes phosphorylation. No migration in
FT                   response to chemokine CXCL12/SDF-1-alpha stimulation; when
FT                   associated with A-2077 and A-2087."
FT                   /evidence="ECO:0000269|PubMed:28028151"
FT   MUTAGEN         2082
FT                   /note="S->E: Phosphomimetic mutant. Enhances migration in
FT                   response to chemokine CXCL12/SDF-1-alpha stimulation and
FT                   reduces interaction with LRCH1; when associated with E-2077
FT                   and E-2087."
FT                   /evidence="ECO:0000269|PubMed:28028151"
FT   MUTAGEN         2087
FT                   /note="S->A: Abolishes phosphorylation. No migration in
FT                   response to chemokine CXCL12/SDF-1-alpha stimulation; when
FT                   associated with A-2077 and A-2082."
FT                   /evidence="ECO:0000269|PubMed:28028151"
FT   MUTAGEN         2087
FT                   /note="S->E: Phosphomimetic mutant. Enhances migration in
FT                   response to chemokine CXCL12/SDF-1-alpha stimulation and
FT                   reduces interaction with LRCH1; when associated with E-2077
FT                   and E-2082."
FT                   /evidence="ECO:0000269|PubMed:28028151"
FT   CONFLICT        22
FT                   /note="A -> V (in Ref. 1; BAE45254)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        470
FT                   /note="S -> I (in Ref. 3; AAI30519/AAI43930)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        600
FT                   /note="V -> VV (in Ref. 4; CAI46160)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1751
FT                   /note="V -> F (in Ref. 6; BAB84907)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1755
FT                   /note="V -> F (in Ref. 6; BAB84907)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1927
FT                   /note="Y -> F (in Ref. 3; AAI30519/AAI43930)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2029
FT                   /note="E -> K (in Ref. 8; AAG42221)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        2046
FT                   /note="L -> F (in Ref. 8; AAG42221)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   2099 AA;  238529 MW;  AF651C26E2D8E73E CRC64;
     MATLPSAERR AFALKINRYS SAEIRKQFTL PPNLGQYHRQ SISTSGFPSL QLPQFYDPVE
     PVDFEGLLMT HLNSLDVQLA QELGDFTDDD LDVVFTPKEC RTLQPSLPEE GVELDPHVRD
     CVQTYIREWL IVNRKNQGSP EICGFKKTGS RKDFHKTLPK QTFESETLEC SEPAAQAGPR
     HLNVLCDVSG KGPVTACDFD LRSLQPDKRL ENLLQQVSAE DFEKQNEEAR RTNRQAELFA
     LYPSVDEEDA VEIRPVPECP KEHLGNRILV KLLTLKFEIE IEPLFASIAL YDVKERKKIS
     ENFHCDLNSD QFKGFLRAHT PSVAASSQAR SAVFSVTYPS SDIYLVVKIE KVLQQGEIGD
     CAEPYTVIKE SDGGKSKEKI EKLKLQAESF CQRLGKYRMP FAWAPISLSS FFNVSTLERE
     VTDVDSVVGR SSVGERRTLA QSRRLSERAL SLEENGVGSN FKTSTLSVSS FFKQEGDRLS
     DEDLFKFLAD YKRSSSLQRR VKSIPGLLRL EISTAPEIIN CCLTPEMLPV KPFPENRTRP
     HKEILEFPTR EVYVPHTVYR NLLYVYPQRL NFVNKLASAR NITIKIQFMC GEDASNAMPV
     IFGKSSGPEF LQEVYTAVTY HNKSPDFYEE VKIKLPAKLT VNHHLLFTFY HISCQQKQGA
     SVETLLGYSW LPILLNERLQ TGSYCLPVAL EKLPPNYSMH SAEKVPLQNP PIKWAEGHKG
     VFNIEVQAVS SVHTQDNHLE KFFTLCHSLE SQVTFPIRVL DQKISEMALE HELKLSIICL
     NSSRLEPLVL FLHLVLDKLF QLSVQPMVIA GQTANFSQFA FESVVAIANS LHNSKDLSKD
     QHGRNCLLAS YVHYVFRLPE VQRDVPKSGA PTALLDPRSY HTYGRTSAAA VSSKLLQARV
     MSSSNPDLAG THSAADEEVK NIMSSKIADR NCSRMSYYCS GSSDAPSSPA APRPASKKHF
     HEELALQMVV STGMVRETVF KYAWFFFELL VKSMAQHVHN MDKRDSFRRT RFSDRFMDDI
     TTIVNVVTSE IAALLVKPQK ENEQAEKMNI SLAFFLYDLL SLMDRGFVFN LIRHYCSQLS
     AKLSNLPTLI SMRLEFLRIL CSHEHYLNLN LFFMNADTAP TSPCPSISSQ NSSSCSSFQD
     QKIASMFDLT SEYRQQHFLT GLLFTELAAA LDAEGEGISK VQRKAVSAIH SLLSSHDLDP
     RCVKPEVKVK IAALYLPLVG IILDALPQLC DFTVADTRRY RTSGSDEEQE GAGAINQNVA
     LAIAGNNFNL KTSGIVLSSL PYKQYNMLNA DTTRNLMICF LWIMKNADQS LIRKWIADLP
     STQLNRILDL LFICVLCFEY KGKQSSDKVS TQVLQKSRDV KARLEEALLR GEGARGEMMR
     RRAPGNDRFP GLNENLRWKK EQTHWRQANE KLDKTKAELD QEALISGNLA TEAHLIILDM
     QENIIQASSA LDCKDSLLGG VLRVLVNSLN CDQSTTYLTH CFATLRALIA KFGDLLFEEE
     VEQCFDLCHQ VLHHCSSSMD VTRSQACATL YLLMRFSFGA TSNFARVKMQ VTMSLASLVG
     RAPDFNEEHL RRSLRTILAY SEEDTAMQMT PFPTQVEELL CNLNSILYDT VKMREFQEDP
     EMLMDLMYRI AKSYQASPDL RLTWLQNMAE KHTKKKCYTE AAMCLVHAAA LVAEYLSMLE
     DHSYLPVGSV SFQNISSNVL EESVVSEDTL SPDEDGVCAG QYFTESGLVG LLEQAAELFS
     TGGLYETVNE VYKLVIPILE AHREFRKLTL THSKLQRAFD SIVNKDHKRM FGTYFRVGFF
     GSKFGDLDEQ EFVYKEPAIT KLPEISHRLE AFYGQCFGAE FVEVIKDSTP VDKTKLDPNK
     AYIQITFVEP YFDEYEMKDR VTYFEKNFNL RRFMYTTPFT LEGRPRGELH EQYRRNTVLT
     TMHAFPYIKT RISVIQKEEF VLTPIEVAIE DMKKKTLQLA VAINQEPPDA KMLQMVLQGS
     VGATVNQGPL EVAQVFLAEI PADPKLYRHH NKLRLCFKEF IMRCGEAVEK NKRLITADQR
     EYQQELKKNY NKLKENLRPM IERKIPELYK PIFRVESQKR DSFHRSSFRK CETQLSQGS
//
